Breast Cancer Clinical Trial
— RESPIREOfficial title:
Pilot Study in Cancer Patients Scheduled for Surgery Evaluating Different Smoking Cessation Protocols : Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy
Verified date | February 2024 |
Source | Institut Cancerologie de l'Ouest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial offers support and assistance to patients wishing to quit smoking in order to increase the success rate of smoking cessation and all the benefits associated with it. Patients will be monitored by a tobacco specialist and will be able to benefit from one or more therapies complementary to Nicotine Replacement Therapy (NRT): Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy.
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years. - Smoking patient: daily tobacco consumption. - Patient with cancer requiring surgical treatment (breast cancer, digestive cancer, gynecological). - Patient wishing to quit smoking. - Fagerström > 3. - Patient has valid health insurance - Information and agreement of the patient to participate in the longitudinal cohort. - Signing of specific informed consent for patients in groups 1 to 4 before any study-related intervention. - Person able to speak, read and understand French. Exclusion Criteria: - Patient not receiving surgical treatment. - Refusal to participate in the longitudinal cohort study. - Pregnant or likely to be pregnant or nursing patient. - Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian - disability to undergo the medical follow-up of the trial for geographical, social or psychological reasons. |
Country | Name | City | State |
---|---|---|---|
France | Institut de Cancerologie de l'Ouest (ICO) | Saint-Herblain |
Lead Sponsor | Collaborator |
---|---|
Institut Cancerologie de l'Ouest | National Cancer Institute, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery | Number of patients who completed all planned sessions out of the total number of patients randomised to each group | 12 months | |
Secondary | Evaluate the efficacy of the following interventions for smoking cessation in French cancer patients: MI, CBT and Hypnotherapy, combined with nicotine replacement therapy | Percentage of patients with an exhaled Carbone Monoxide (CO) measurement < 10 ppm at study visits. | 12 months | |
Secondary | Evaluate the efficacy of the following interventions for smoking cessation in French cancer patients: MI, CBT and Hypnotherapy, combined with nicotine replacement therapy | Percentage of patients reporting no smoking during the last 7 days before the visit. | 12 months | |
Secondary | Evaluate the efficacy of the different interventions in reducing tobacco consumption | Number of cigarettes smoked per day from baseline | 12 months | |
Secondary | Evaluate the efficacy of the different interventions in terms of continued abstinence since surgery | Percentage of patients reporting no smoking since surgery | 12 months | |
Secondary | Evaluate the reduction in side effects of oncological treatments after smoking cessation | Report all Grade > 1 side effects of oncology treatments up to 3 months after the end of treatment or the end of the study | 3 month | |
Secondary | Estimate the decrease in surgical complications | Report all surgical complications (Grade > 1 according to Clavien Dindo classification) up to 1 month after surgery | 1 month | |
Secondary | Evaluate the efficacy of interventions on patient depression and anxiety | Patient Depression and anxiety will be evaluated by using the Hospital Anxiety and Depression Scale (HADS) | 12 months | |
Secondary | Evaluate the efficacy of interventions on patient quality of life | Patient quality of life will be evaluated by using the Quality of Life Questionnaire (QLQ-C30) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |